| Total (n = 276) | Non-clozapine group (n = 161) | Clozapine group (n = 115) |  | p | ||
---|---|---|---|---|---|---|---|
Mean or n (%) | S.D. | Mean or n (%) | S.D. | Mean or n (%) | S.D. | Â | |
Male sex n (%) | 152 (55.1%) | Â | 85 (52.8%) | Â | 67 (58.3%) | Â | 0.368 |
Schizophrenia | 190 (68.8%) |  | 89 (55.3%) |  | 101 (87.8%) |  | < 0.001 |
Schizoaffective disorder | 49 (17.8%) | Â | 36 (22.4%) | Â | 13 (11.3%) | Â | 0.018 |
Other schizophrenia spectrum disorder | 37 (13.4%) |  | 36 (22.4%) |  | 1 (0.9%) |  | < 0.001 |
Age | 44.9 | 12.6 | 47.2 | 12.5 | 41.8 | 12.1 | 0.001 |
Chlorpromazine equivalents, mg | 582.5 | 423.2 | 415.3 | 344.1 | 816.7 | 413.6 | < 0.001 |
ANT-attitude (0–100) | 72.0 | 16.5 | 71.1 | 17.0 | 73.3 | 15.8 | 0.334 |
ANT-adherence (over 75%) | 228 (82.6%) | Â | 124 (77.0%) | Â | 104 (90.4%) | Â | 0.004 |
ANT-insight (0–100) | 49.5 | 24.9 | 46.5 | 24.7 | 53.7 | 24.7 | 0.024 |
ANT-side effects (0–100) | 62.4 | 24.0 | 64.0 | 25.5 | 60.2 | 21.6 | 0.175 |
BPRS (24–168) | 34.6 | 7.8 | 34.4 | 8.1 | 34.9 | 7.4 | 0.363 |
BPRS positive symptoms (7–49) | 10.2 | 4.3 | 10.1 | 4.4 | 10.3 | 4.1 | 0.58 |
HoNOS total (0–48) | 7.2 | 4.5 | 7.1 | 4.5 | 7.3 | 4.4 | 0.712 |
HoNOS behaviour (0–12) | 0.3 | 0.7 | 0.4 | 0.8 | 0.2 | 0.6 | 0.02 |
HoNOS impairment (0–8) | 1.8 | 1.6 | 1.8 | 1.7 | 1.7 | 1.5 | 0.853 |
HoNOS symptoms (0–12) | 3.0 | 2.2 | 2.9 | 2.2 | 3.3 | 2.2 | 0.139 |
HoNOS social (0–16) | 1.2 | 1.3 | 1.2 | 1.4 | 1.2 | 1.3 | 0.591 |
SANS (0–15) | 1.1 | 1.0 | 1.1 | 1.0 | 1.1 | 1.0 | 0.712 |
GAF (0–100) | 56.1 | 12.6 | 57.6 | 12.5 | 54.0 | 12.5 | 0.022 |
ADL (5–20) | 5.7 | 1.3 | 5.8 | 1.5 | 5.4 | 0.9 | 0.061 |
IADL (5–20) | 7.6 | 2.8 | 7.8 | 3.1 | 7.3 | 2.3 | 0.422 |
Social functioning (4–16) | 5.5 | 1.9 | 5.6 | 1.9 | 5.5 | 1.8 | 0.897 |